For ICI-based therapies to provide maximum benefit to NPC patients, a number of markers that predict the efficacy of immunotherapy have been identified over the years, including tumor mutation burden (TMB) [25, 26], tumor infiltrating lymphocytes (TILs) [27] detection, and PD-L1 expression in tumor tissue [28, 29]. Here, CD274 is linked to neoplasm.